PAREXEL International

472 articles with PAREXEL International

• PAREXEL Announces Change to Board of Directors

  12/13/2018

  Josef von Rickenbach will step down as Chairman of the Board of Directors effective December 31, 2018.

• PAREXEL Collaborates with Eli Lilly and Company to Develop China’s Clinical Research Workforce

  12/5/2018

  The program will bring high-value training opportunities to China’s clinical trial sites and investigators, enhancing the execution of local clinical trials and driving innovation in China’s biopharmaceutical industry.

• 

  Roivant Sciences Raises $200 Million, Bringing Its Valuation to $7 Billion

  11/13/2018

  Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.

• PAREXEL Announces Appointment of New Members to Its Board of Directors

  11/12/2018

  Today announced the appointment of new members to the Board of Directors following Pamplona Capital Management’s acquisition in September 2017.

• PAREXEL Navigates China’s Complex Drug Development and Market Landscape for Global Biopharmaceutical Companies with New China Advisory Service

  10/31/2018

  The offering leverages PAREXEL’s deep experience with and knowledge of the Chinese biopharmaceutical landscape to help companies navigate all aspects of the country’s drug development process.

• PAREXEL Announces Several New Patient-Centric Innovations to Address Drug Development Challenges

  10/9/2018

  Solutions Built on the Perceptive Cloud Platform Leverage Mobile and Wearable Technology

• PAREXEL Advances Patient-Centric Drug Development with Introduction of Its Patient Innovation Center

  9/11/2018

  The Center can help sponsors improve the drug development process by reducing the practical, financial and geographical barriers patients and caregivers often face, and optimize patient involvement and engagement.

• PAREXEL’s Xavier Flinois Named to 2018 PharmaVOICE 100

  8/1/2018

  PAREXEL International Corporation announced that Xavier Flinois, President of PAREXEL Informatics, has been named to PharmaVOICE magazine’s list of the 100 most inspiring people in the life sciences industry.

• 

  Biotech Manufacturing is Booming with Growth of Biologics and Gene Therapies

  7/5/2018

  Manufacturing is the non-glamorous side of biopharma, although its impact on the economy shouldn’t be underestimated.

• PAREXEL to Lead Discussions on Global Drug Development, Unveil New Industry Research at DIA Annual Meeting

  6/18/2018

  PAREXEL International Corporation announced today that several of its experts will discuss key issues facing the industry at the 54th Drug Information Association (DIA) Annual Meeting

• PAREXEL Receives Multiple Industry Recognitions for its Service to the Life Sciences Industry

  5/30/2018

  PAREXEL International Corporation announced that the Company has received recognition for its service and expertise from several notable industry organizations.

• Mark A. Goldberg, MD Joins Intensity Therapeutics, Inc. Board of Directors

  5/17/2018

  Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immune-based drug products for direct intratumoral injection, today announced that Mark A. Goldberg, MD has been appointed to the Company's Board of Directors effective May 1, 2018.

• University of Texas System Initiative, Clinical Trials Xpress (CTX), Named as a PAREXEL Strategic Site Alliance Network Member

  4/26/2018

  Clinical Trials Xpress has been named by PAREXEL, the world's leading innovator of biopharmaceutical services, as a member of its Global Site Alliance Network.

• PAREXEL Announces Appointment of Peyton Howell as Chief Commercial and Strategy Officer

  4/25/2018

  Proven Healthcare Industry Leader will head PAREXEL’s Commercial Strategy

• PAREXEL’s Randomization and Trial Supply Management Service Recognized as Leader in Second Consecutive Industry Standard Research Benchmark Report

  4/17/2018

  PAREXEL’s ClinPhone® Randomization and Trial Supply Management cited as the most preferred and widely used Interactive Response Technology solution

• PAREXEL and Meiji Pharmaceutical University Announce Academic Program to Develop Japan’s Biopharmaceutical Workforce

  4/9/2018

  Joint Program for Clinical Research and Clinical Trial Management to be offered through the PAREXEL Academy

• PAREXEL Introduces Integrated Medical Writing Solutions Service Offering

  3/21/2018

  Comprehensive end-to-end services enable effective, streamlined communication with key stakeholders across all stages of drug development and commercialization

• PAREXEL and CHA Medical Group Partner to Enhance Early Phase Clinical Research in Korea

  3/13/2018

  Collaboration combines best-in-class offerings from CHA and PAREXEL to enhance early phase clinical trials in growing hub for drug development

• 

  Parexel International Taps New CEO Jamie Macdonald

  3/6/2018

  After 35 years at the helm of Parexel International Corporation, co-founder Josef von Rickenbach is stepping down from his role as chief executive officer.

• PAREXEL Appoints Jamie Macdonald as Chief Executive Officer

  3/5/2018

  PAREXEL International Corporatio announced the appointment of Jamie Macdonald as Chief Executive Officer (CEO) effective March 15, 2018.